Electra Therapeutics, Inc.
corporate_fare Company Profile
Electra Therapeutics, Inc. (NASDAQ:ETRA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 5 items for ETRA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-25, rated 7/10. Across its 5 most recent items scored 7 or higher, the top rating is 8/10, with 3 rated 8 or above. Recent SEC coverage for ETRA spans SCHEDULE 13D, 4, 424B4.
Recent high-impact activity:
- OrbiMed Discloses 11% Stake in Electra Therapeutics After IPO Conversion
- ADARx Soars 30% in Debut After $446M Upsized IPO; AbbVie Takes 4.9% Stake
- OrbiMed Buys $20M in Electra IPO, Converts $69M Preferred Stake
- Electra Therapeutics Prices $350M IPO at $15/Share, Lists on Nasdaq as ETRA
- Electra Therapeutics Raises $350M in Offering
Short Interest & Short Volume
On October 2, 2026, 31.3% of ETRA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for ETRA, detected from its recent SEC filings · based on capital-structure filings through 2026-09-18.
IPO Priced at $15.00 Per Share · Net Proceeds of $319.9 Million
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →